Skip to main content
The BMJ logoLink to The BMJ
. 1998 Feb 14;316(7131):618–620. doi: 10.1136/bmj.316.7131.618

The new genetics in clinical practice

John Bell 1
PMCID: PMC1112641  PMID: 9518921

Full Text

The Full Text of this article is available as a PDF (475.5 KB).

Figure.

Figure

Understanding of how genes might modify our susceptibility to disease is evolving

Footnotes

Funding: Wellcome Fund.

Conflict of interest: JB sits as a non-executive member on the board of Oxagen, a genomic biotechnology company, but holds no equity.

References

  • 1.Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahen R, Grzelcak Z, et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science. 1989;245:1066–1073. doi: 10.1126/science.2475911. [DOI] [PubMed] [Google Scholar]
  • 2.European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 1994;77:881-6. [DOI] [PubMed]
  • 3.Schuler GD, Boguski MS, Stewart EA, Stein LD, Gyapay G, Rice K, et al. A gene map of the human genome. Science. 1996;274:540–546. [PubMed] [Google Scholar]
  • 4.Marshall E. Genome researchers take the pledge. Science. 1996;272:477–478. doi: 10.1126/science.272.5261.477b. [DOI] [PubMed] [Google Scholar]
  • 5.To affinity ... and beyond [editorial]. Nature Genet 1996;14:367-70. [DOI] [PubMed]
  • 6.Ludworth AG, Woodrow JC. HL-A antigens and diabetes mellitus. Lancet. 1974;2:1153. doi: 10.1016/s0140-6736(74)90930-1. [DOI] [PubMed] [Google Scholar]
  • 7.Miki Y, Swensen J, Shattuck-Eidens D, Fureal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRACT. Science. 1994;266:66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  • 8.Wooster R, Bignell G, Lancester J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]
  • 9.Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170. doi: 10.1016/s0092-8674(00)81333-1. [DOI] [PubMed] [Google Scholar]
  • 10.Yamagata K, Hiroto F, Oda N, Kaisaka PJ, Menzel S, Cos NJ, et al. Mutations in the hepatocyte nuclear factor-4a gene in maturity-onset diabetes of the young (MODY1) Nature. 1996;384:458–460. doi: 10.1038/384458a0. [DOI] [PubMed] [Google Scholar]
  • 11.Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, et al. Familial hyperglycemia due to mutations in glycokinase: definition of a subtype of diabetes mellitus. N Engl J Med. 1993;328:697–702. doi: 10.1056/NEJM199303113281005. [DOI] [PubMed] [Google Scholar]
  • 12.Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the hepatocyte nuclear factor-1a gene in maturity-onset diabetes of the young (MODY3) Nature. 1996;384:455–458. doi: 10.1038/384455a0. [DOI] [PubMed] [Google Scholar]
  • 13.Roses A. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer’s disease. Ann Neurol. 1995;38:6–14. doi: 10.1002/ana.410380105. [DOI] [PubMed] [Google Scholar]
  • 14.Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–644. doi: 10.1038/359641a0. [DOI] [PubMed] [Google Scholar]
  • 15.Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169–180. doi: 10.1016/0092-8674(92)90275-h. [DOI] [PubMed] [Google Scholar]
  • 16.Schmidt S, Schone N, Ritz E. Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int. 1995;47:1176–1181. doi: 10.1038/ki.1995.167. [DOI] [PubMed] [Google Scholar]
  • 17.Ridker PM, Miletick JP, Stampfer MJ, Goldhaber SZ, Linkpainter K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800–2802. doi: 10.1161/01.cir.92.10.2800. [DOI] [PubMed] [Google Scholar]
  • 18.Nebert DW. Polymorphisms in drug-metabolising enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 997;60:265-71. [PMC free article] [PubMed]
  • 19.Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effects of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES